Ask AI
NHL ALL From EHA ICML 2025
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Released: July 28, 2025

Expiration: January 27, 2026

Activity

Progress
1
Course Completed

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts:

  • POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
  • ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
  • CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
  • InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
  • SHR2554: Oral EZH2 Inhibitor in R/R PTCL
  • SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL